AN UNBIASED VIEW OF LINK ALTERNATIF MBL77

Unfit patients also have the alternative of venetoclax additionally obinutuzumab (VO) as frontline therapy. This is predicated on the stage III trial that compared VO with ClbO in aged/unfit sufferers.113 VO was top-quality concerning response charge and progression-no cost survival, and experienced a equivalent protection profile. In this trial VO